Original ArticleBiomedicalMicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN
Introduction
Breast cancer is one of the leading causes of cancer death in females worldwide. Approximately 1,200,000 patients were newly diagnosed with breast cancer annually worldwide and about 465,000 will die from the disease (1). In China, about 40,000 patients die from breast cancer every year. Despite the use of multiple therapies including chemotherapy, the tumor does not actively respond to the therapies (2). Therefore, a better understanding of the molecular mechanisms involved in breast cancer formation and progression will be helpful for identification of sensitive tumor markers so as to develop novel chemotherapeutic drugs and preventive strategies for breast cancer therapy.
MicroRNAs (miRNAs), a class of small noncoding RNAs first reported in 1993, are posttranscriptional regulators of gene expression and have been shown to be involved in cell differentiation, survival and apoptosis (3). Aberrant posttranscriptional regulation of mRNAs by miRNAs can lead to oncogenesis with increased cell proliferation, decreased apoptosis, and enhanced metastatic potential of affected cells (4). Thus, dysregulation of miRNAs could play critical roles in tumorigenesis and tumor progression. However, their associations with chemosensitivity of human tumors are still not elucidated systematically. MiR-21 is a miRNA, which has been reported to be overexpressed in many human malignancies and acts as an oncogene related to proliferation, apoptosis, and metastasis 5, 6, 7. Asgaga et al. showed that circulating miR-21 is a potential diagnostic and prognostic biomaker in breast cancer (8). Huang and colleagues reported that high expression of miR-21 indicates a more aggressive phenotype for breast cancer patients (9). Additionally, other groups showed that miR-21 could affect invasion and metastasis of breast cancer 10, 11. To the best of our knowledge, there have been no reports about the expression of miR-21 and sensitivity of breast cancer cells to ADR.
In the present study we provide the first evidence that miR-21 regulates ADR resistance of breast cancer cells, at least in part, by targeting the tumor suppressor gene PTEN. These data showed that miR-21 targeting therapy may be a potential strategy for chemosensitization of breast cancer.
Section snippets
Cell Culture
Human breast cancer cell line MCF-7 and its doxorubicin-resistant variant MCF-7/ADR (obtained from Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai, China) were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (Gibco BRL, Grand Island, NY) in a humidified atmosphere containing 5% CO2 at 37°C. To maintain the ADR-resistance phenotype, ADR (with final concentration of 1.0 μmol/L) was added to the culture media for MCF-7/ADR cells.
Construction of Plasmid Vectors
Previously, the
Expression of miR-21 and PTEN Protein in MCF-7 and Paired MCF-7/ADR Cells
First, MTT assay was performed to determine the IC50 value of ADR in sensitive MCF-7 and resistant MCF-7/ADR cells. As shown in Figure 1A, the IC50 of ADR in MCF-7 and MCF-7/ADR cells was 0.21 ± 0.05 and 16.5 ± 0.08 μmol/L, respectively (p <0.01). Then, TaqMan RT-PCR assay was performed to detect the expression of miR-21 in breast cancer cell line (MCF-7) and paired ADR-resistant breast cancer cell line (MCF-7/ADR). Compared with that in MCF-7 cell line, the relative level of miR-21 expression
Discussion
Aberrant expression of miRNAs has been reported to be involved in tumor progression, metastasis and chemoradioresistance (12). Among them, miR-21 was one of the first miRNAs detected in the human genome and is the only miRNA known to be overexpressed in a variety of human cancers. Previously, much evidence has shown that miR-21 is found to be correlated with prognosis of tumor patients, indicating that it may be used as a molecular marker for predicting patient prognosis 13, 14. In addition,
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (No. 30973477), the Natural Science Foundation of Jiangsu Province (No. BK2010590), the Jiangsu Provincial Personnel Department “the Great of Six Talented Man Peak” Project (No. 09-B1-021 and 2010-IB10), Qing Lan Project 2010 of Jiangsu Province Department of Education, and the Foundation of Nanjing Medical University (09NMUZ21).
References (27)
- et al.
MicroRNAs: synthesis, mechanism, function, and recent clinical trials
Biochim Biophys Acta
(2010) - et al.
Roles of small RNAs in tumor formation
Trends Mol Med
(2010) - et al.
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity
Brain Res
(2010) - et al.
Programmed cell death 4 (PDCD4) is an important functional target of the microRNAmiR-21 in breast cancer cells
J Biol Chem
(2008) - et al.
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer
Gastroenterology
(2007) - et al.
MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC)
Clin Chim Acta
(2010) - et al.
Cancer statistics, 2009
CA Cancer J Clin
(2009) Breast cancer
J R Coll Physicians Edinb
(2010)- et al.
MicroRNAs as cancer players: potential clinical and biological effects
DNA Cell Biol
(2007) - et al.
MicroRNAs as gatekeepers of apoptosis
J Cell Physiol
(2010)
MicroRNAs and metastasis: little RNAs go a long way
Cancer Res
Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer
Clin Chem
Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma
Oncol Rep
Cited by (133)
Association of microRNA-21 expression with breast cancer subtypes and its potential as an early biomarker
2024, Pathology Research and PracticeDoxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
2023, Molecular Aspects of MedicineBeneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review
2023, International Journal of Biological MacromoleculesCitation Excerpt :Moreover, the expression of miR-130a is significantly higher in tumor tissues of patients sensitive to neoadjuvant therapy than those of resistant patients. Regarding miR-21, it was reported that its upregulation imparts resistance to doxorubicin, an effect that may be due to targeting PTEN [186] (Table 3). Besides the role of miRNAs in doxorubicin resistance, they also have an important role in the response of cancer cells to taxanes, adriamycin, and platinum-based therapy.
Overview of non-coding RNAs in breast cancers
2022, Translational OncologyCalcium phosphate-polymeric nanoparticle system for co-delivery of microRNA-21 inhibitor and doxorubicin
2021, Colloids and Surfaces B: Biointerfaces
- ∗
These authors contributed equally to this work.